The complaint that sounds simple and isn’t
“My lower face is sagging. I want it tightened.”
It is one of the most common concerns we hear in consultations — and one of the most deceptive, because the sentence sounds like it describes a single problem. In practice, it almost never does.
The lower third of the face is a region where at least four distinct anatomical processes contribute to the changes patients describe. Fat accumulation, skin laxity, muscle changes, and skeletal resorption can all produce a version of “my jawline is softer than it used to be” or “I have a double chin now” — but they require completely different treatments. A device selected without knowing which of these is driving the change has a meaningful chance of producing underwhelming results, because it is solving the wrong problem.
This is not a criticism of any device in particular. It is a structural property of the lower face: it is where multiple aging mechanisms converge, and where confident-sounding treatment recommendations are most likely to be mismatched to the actual anatomy.
What actually causes a double chin?
The answer is not always fat — and this matters more than it might seem.
Submental adipose tissue is the most commonly assumed cause. There is a defined fat compartment beneath the chin and above the platysma muscle, and in some patients this compartment is genuinely enlarged — either constitutionally, from weight gain, or from the downward migration of facial fat with age. When this is the primary driver, treatments targeting fat have a rationale.
Skin laxity is the second, frequently underweighted cause. As the dermis thins and collagen architecture degrades, the skin of the neck and submental area loses its tension. Even patients with relatively modest submental fat can develop the appearance of a double chin purely because the skin no longer holds its position. In these patients, fat-targeting devices do nothing useful — and can occasionally worsen the appearance by softening the tissue without addressing the overlying laxity.
Platysmal banding is a third mechanism that tends to be overlooked entirely in device-centered discussions. The platysma is a broad, flat muscle running from the chest up across the anterior neck. With age, the medial edges of this muscle separate and become visible as vertical bands. This is a muscular phenomenon and responds to different interventions than either fat or skin laxity.
Mandibular bone resorption is the fourth driver, and the one least often discussed in non-surgical settings. The angle of the mandible resorbs with age; the chin region narrows and loses definition; and the soft tissue that once draped over a more defined skeletal frame no longer has the support it once did. You cannot tighten bone into existence with any device. What you can do — in some cases — is restore the structural relationship between the bone and the overlying tissue through careful filler work, accepting that the “lifting” complaint is actually partly a structural deficit problem.
Why does this breakdown matter clinically?
Because the treatment implications diverge almost completely depending on which mechanism is primary.
A patient whose lower face concern is driven predominantly by submental fat benefits from a treatment that addresses that compartment: injectable deoxycholic acid, targeted body contouring devices, or in more pronounced cases, surgical liposuction. The skin envelope matters, but it is secondary.
A patient whose concern is driven primarily by skin laxity and collagen loss needs a treatment that remodels the dermis and tightens the skin — not one that removes fat. Removing fat from a face where the skin is already lax tends to worsen the appearance of ptosis.
A patient with platysmal banding may benefit from neuromodulator injection to relax and partially flatten the bands — a very different intervention from any lifting device.
And a patient with significant mandibular resorption needs a structural conversation about whether the frame can be partly reconstituted before any lifting makes visual sense.
In most patients we see, more than one of these mechanisms is active. But they are rarely present in equal proportion, and identifying which one is dominant changes the treatment hierarchy completely.
What does Ultherapy actually do in the lower face?
Ultherapy — and HIFU (High Intensity Focused Ultrasound) devices in general — delivers focused energy to a specific depth, typically the SMAS layer and the platysma. This is the layer that surgeons address during a traditional facelift: a fibromuscular plane that, when contracted and repositioned, produces structural lifting.
In the lower face, HIFU at SMAS depth creates a thermal coagulation response that induces contraction and subsequent collagen remodeling over three to six months. The clinical effect, when the indication is correct, is a genuine structural change — not surface tightening, but a reorganization of the deeper support architecture.
This makes HIFU well-suited for patients whose primary complaint is structural descent: the loss of definition along the jawline driven by ligamentous laxity and fascial softening, rather than skin surface changes. For a broader comparison of how HIFU differs mechanistically from RF devices, Why Lifting Comparisons Mislead Patients covers this in some depth.
HIFU is less well-suited as a primary approach for patients whose main issue is fat or skin surface laxity. It reaches a depth that bypasses the dermal layer. If the problem is in the dermis, the energy is passing through without addressing it.
What does Thermage FLX do in the lower face?
Thermage uses monopolar radiofrequency energy to heat the dermis uniformly. The thermal effect on collagen fibers produces immediate contraction (visible in some patients within days) and a slower remodeling process over months.
The clinical implication for the lower face: Thermage is primarily a skin-envelope treatment. It addresses the dermal layer where collagen architecture lives. In patients with genuine skin laxity — where the skin surface itself has lost its tensile properties — Thermage produces visible improvement in the quality and tightness of the skin envelope.
For patients with submental fullness driven primarily by fat, Thermage addresses the skin layer but does not meaningfully reduce the fat compartment. For patients with structural SMAS descent, it addresses a shallower plane than the problem. The indication, again, determines whether the device is relevant.
For a more complete picture of how Thermage and Ultherapy target different anatomical planes, Lifting Devices Compared remains a useful reference.
What about devices targeting fat and skin simultaneously?
There is a category of devices — most commonly cited in this context are ONDA, InMode Morpheus8, and radiofrequency microneedling platforms — that claim to address both fat reduction and skin tightening within a single treatment. The underlying principle is sound: RF energy can be delivered at a depth that reaches the superficial fat layer while the fractional or bipolar delivery pattern also creates dermal remodeling.
The clinical reality is that this category works well in patients with a relatively specific profile: genuine submental fat, co-existing skin laxity, and a profile that is not severe enough to require surgical intervention. Outside that profile, the results tend to be modest.
We observe a pattern in consultations where patients have been told a combined-mechanism device will “take care of everything” — the double chin, the sagging, and the skin quality simultaneously. This is rarely the full picture. Combined-mechanism devices are genuinely useful tools in the right hands, applied to the right indication. But the marketing framing around them tends to overstate the breadth of what any single device can accomplish, which is why the diagnostic step matters so much before any device is chosen.
What about thread lifts?
Threads deserve an honest characterization. A polydioxanone (PDO) or PCL thread inserted into the submental or lower-face region can produce visible improvement in the contour — sometimes dramatically so in the first weeks after treatment. The lifting vector is mechanical, and when the thread is placed correctly, the initial result reflects genuine tissue repositioning.
The durability question is where thread lift counseling often falls short. PDO threads are absorbed within about six months. PCL threads last somewhat longer. During and after absorption, the thread generates some fibrosis and collagen deposition, which is the intended secondary mechanism. But in many patients, the improvement at six months is meaningfully less than it was at four weeks.
Thread lifts are a legitimate option for patients who want a visible short-term improvement in lower-face contour, understand the durability profile clearly, and are not candidates for or interested in energy device protocols or surgery. They are poorly suited as a long-term strategy. Framing them as a permanent alternative to either devices or surgery is one of the more persistent oversimplifications in this category.
When should surgical referral be on the table?
This is a question that non-surgical clinics sometimes avoid, which is itself a clinical problem.
When the severity of structural descent — the degree of platysmal laxity, the extent of jowling, the depth of submental ptosis — exceeds what energy devices can reasonably address in a patient’s timeline and budget, surgery is not a failure mode. It is the appropriate treatment.
The threshold for that conversation varies by patient and by how aggressively they want to address the concern. But a few patterns suggest that a surgical consult is the more honest recommendation: substantial submental fat that is not responding to non-surgical approaches, significant platysmal banding that neuromodulators cannot adequately address, and jowl descent severe enough that multiple rounds of HIFU have produced diminishing returns.
We hold to a principle that the boundaries of non-surgical treatment should be declared honestly — not because surgical patients are not our patients, but because patients who spend eighteen months pursuing non-surgical results on a problem that needed surgery are poorly served by the avoidance of that conversation.
How do combined cases get sequenced?
The majority of patients with lower-face concerns present with a combination of mechanisms. A 45-year-old with moderate submental fat, early skin laxity, and beginning jowl descent has elements of all three. The sequencing logic follows a general principle: address the deeper architectural layers before or simultaneously with the surface ones, and assess skin quality separately from structural change.
In practice, for a patient with fat and laxity co-present, this often means addressing the fat compartment first (if it is significant), then allowing the skin response to that change to be evaluated before deciding how much additional skin tightening is needed. Treating the skin layer aggressively before fat reduction may result in redundant skin after fat is addressed — a problem that requires additional treatment.
For a patient with SMAS descent and skin laxity co-present, HIFU and Thermage can be combined in the same session or in sequential sessions, each targeting a different layer. This is not gratuitous combination — it is mechanistically rational when the problem spans both depths. The Structural Reset protocol and the layered approach within Signature Lifting are designed around exactly this logic.
For patients whose lower-face concern combines structural descent with declining tissue quality — a pattern that becomes more common in the late forties and beyond — the Metacell Protocol is designed for the combined picture directly. Autologous PRP and photobiomodulation prime the dermal and subdermal tissue; the physician then selects the energy layer — most commonly Ultherapy at SMAS depth, sometimes paired with Thermage for skin-envelope work — that addresses the specific structural priority. The regenerative layer changes how durable the energy work is, which matters more in older or thinner tissue.
The Korean Lifting Guide offers additional orientation for international patients approaching this category for the first time, and How to Choose the Right Lifting Treatment walks through the decision framework in more accessible terms.
The lower face as a diagnostic challenge
The lower face is not a simple target. It is where the face’s four major aging mechanisms — fat, skin, muscle, and bone — converge in a small anatomical region, and where the appearance of a single complaint can emerge from very different structural stories.
The consequence for treatment planning is that the lower third deserves a more careful diagnostic conversation than most other areas of the face. Not because the treatments are more complicated, but because the cost of a diagnostic mismatch is highest here. A mismatched treatment in this region produces a result that looks wrong in a way that is difficult to characterize — not dramatically bad, but not quite right, and hard to explain without reference to the underlying anatomy.
Understanding what is driving the change, before choosing how to address it, is the most important step in the lower-face consultation. The Chamaka-se design method begins there and works forward. The device is the last decision, not the first.
For the published clinical evidence on HIFU and lower-face laxity outcomes, the PubMed literature on submental fullness HIFU treatment provides a useful research starting point. The studies available do reflect the heterogeneity of indication and outcomes that this article has attempted to explain.
This article is intended for educational purposes. It does not constitute a clinical recommendation or treatment guide. Individual treatment plans for lower-face concerns should be determined through direct physician consultation, which includes assessment of your specific anatomy, prior treatment history, and expectations. Contact Tune Clinic to discuss your situation.
